# Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

> **NCT03397134** · PHASE3 · COMPLETED · sponsor: **Minerva Neurosciences** · enrollment: 515 (actual)

## Conditions studied

- Negative Symptoms of Schizophrenia

## Interventions

- **DRUG:** Placebo Oral Tablet
- **DRUG:** Roluperidone 32 mg
- **DRUG:** Roluperidone 64 mg

## Key facts

- **NCT ID:** NCT03397134
- **Lead sponsor:** Minerva Neurosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2020-05-26
- **Final completion:** 2021-02-15
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03397134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03397134, "Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03397134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*